In progressive diffuse large B-cell lymphoma (DLBCL) patients with Rituximab-resistant TP53 mutations, Chidamide may play a chemo-sensitizing role by inhibiting the transcription and translation of mutant TP53 and up-regulating the surface expression of CD20 antigen in lymphoma cells (Li et al., 2019). This evidence concerns the gene TP53 and lymphoma.